Donors at risk: proteinuria

被引:7
作者
Boudville, Neil
Kanellis, John
机构
关键词
LIVING KIDNEY DONORS; MICROALBUMINURIA; ALBUMINURIA; POPULATION;
D O I
10.1111/j.1440-1797.2009.01218.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Potential living donors should have their urinary protein excretion measured using either a 24- hour urine collection ( daily excretion) or a spot urine sample ( protein/ creatinine ratio). A urine protein excretion of > 300 mg/ day ( 24 hour collection) or of > 30 mg/ mmol ( spot urine protein/ creatinine ratio) is usually a contraindication to live donation. Further investigations are warranted when urine protein excretion is > 150 mg/day but less than < 300 mg/ day ( corresponds approximately with spot urinary protein/ creatinine of > 15 mg/ mmol but < 30 mg/ mmol). Repeat urinary protein estimation, as well as measurement of urinary albumin excretion may help in further assessing potential living donors. Although overt proteinuria may be absent, the presence of microalbuminuria ( urinary albumin excretion of > 30 mg/ day or > 20 mg/ min; albumin/ creatinine ratio > 2.5 mg/ mmol) should be considered a relative contraindication to live donation. Microalbuminuria or mild proteinuria (< 300 mg/ day) occurring in the presence of another associated clinical or laboratory abnormality ( e. g. hypertension, obesity, glucose intolerance, glomerular haematuria) should be considered a relative contraindication to live donation. In potential living donors with minor degrees of proteinuria or albuminuria, a renal biopsy may help in further assessing the donor's risk of developing progressive renal disease following donation ( Opinion). Donors should have their urinary protein excretion measured as part of their routine, follow- up care. It is recommended that this be performed at least once a year along with blood pressure and serum creatinine measurement ( Opinion).
引用
收藏
页码:S106 / S110
页数:5
相关论文
共 18 条
[1]   Association between albuminuria and proteinuria in the general population: the AusDiab Study [J].
Atkins, RC ;
Briganti, EM ;
Zimmet, PZ ;
Chadban, SJ .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (10) :2170-2174
[2]  
DAlmeida P, 1996, TRANSPLANT P, V28, P93
[3]   Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes [J].
Diercks, GFH ;
Hillege, HL ;
van Boven, AJ ;
Kors, JA ;
Crijns, HJGM ;
Grobbee, DE ;
de Jong, PE ;
van Gilst, WH .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (08) :1401-1407
[4]   No evidence of accelerated loss of kidney function in living kidney donors:: Results from a cross-sectional follow-up [J].
Fehrman-Ekholm, I ;
Dunér, F ;
Brink, B ;
Tydén, G ;
Elinder, CG .
TRANSPLANTATION, 2001, 72 (03) :444-449
[5]   Proteinuria and reduced kidney function in living kidney donors: A systematic review, meta-analysis, and meta-regression [J].
Garg, A. X. ;
Muirhead, N. ;
Knoll, G. ;
Yang, R. C. ;
Prasad, G. V. R. ;
Thiessen-Philbrook, H. ;
Rosas-Arellano, M. P. ;
Housawi, A. ;
Boudville, N. .
KIDNEY INTERNATIONAL, 2006, 70 (10) :1801-1810
[6]  
Gerstein HC, 2000, DIABETES CARE, V23, pB35
[7]   Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals [J].
Gerstein, HC ;
Mann, JFE ;
Yi, QL ;
Zinman, B ;
Dinneen, SF ;
Hoogwerf, B ;
Hallé, JP ;
Young, J ;
Rashkow, A ;
Joyce, C ;
Nawaz, S ;
Yusuf, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (04) :421-426
[8]   Renal outcome 25 years after donor nephrectomy [J].
Goldfarb, DA ;
Matin, SF ;
Braun, WE ;
Schreiber, MJ ;
Mastroianni, B ;
Papajcik, D ;
Rolin, HA ;
Flechner, S ;
Goormastic, M ;
Novick, AC .
JOURNAL OF UROLOGY, 2001, 166 (06) :2043-2047
[9]   Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity [J].
Hillege, HL ;
Janssen, WMT ;
Bak, AAA ;
Diercks, GFH ;
Grobbee, DE ;
Crijns, HJGM ;
van Gilst, WH ;
de Zeeuw, D ;
de Jong, PE .
JOURNAL OF INTERNAL MEDICINE, 2001, 249 (06) :519-526
[10]   Risk of developing end-stage renal disease in a cohort of mass screening [J].
Iseki, K ;
Iseki, C ;
Ikemiya, Y ;
Fukiyama, K .
KIDNEY INTERNATIONAL, 1996, 49 (03) :800-805